Aynechi Tiba 4

What Happened

• Aynechi Tiba, a director of MBX Biosciences, received a grant/award of 12,500 derivative shares on June 4, 2026. The reported acquisition price is $0.00 (no cash paid). The filing classifies this as an award/grant (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely).
• Shares granted: 12,500; price reported: $0.00; total cash consideration: $0.
• Security type: derivative (award/grant); transaction code A.
• Shares owned after the transaction: not specified in the filing.
• Footnote: The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director’s continued service.

Context

• This is a routine non-employee director compensation award rather than a purchase or sale of stock. Awards that vest over time are common for directors and do not by themselves indicate trading sentiment.